With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Join Dr. Tardif as he discusses the latest clinical data addressing heart rate-lowering therapy in patients with stable coronary heart disease and left ventricular systolic dysfunction. The role of heart rate-lowering therapy and target populations are reviewed, as well as the next steps required for application to Canadian medical practice.
Management of long-term anticoagulation therapy in STEMI patients is challenging. Please join our expert panel, Drs. Elaine Hylek, Ander Cohen, Greg Lip, and Jack Ansell, as they discuss current challenges and strategies to optimize the benefit of and provide insights to the future of anticoagulation therapy.
How can we reduce the time taken to accurately diagnose ACS? ECGs and biomarkers may be nondiagnostic, even the presenting symptoms can vary or be absent. As every 30 minutes delay is associated with a 7.5% relative increase in mortality, time is indeed muscle. Join Drs. Gibson, Pride, Santini, and Krucoff as they present new insights into this complex field.
The world's first MR-conditional pacemaker system designed for safe use in MRI represents a major milestone in the evolution of ICDs. Dr. Bruce Wilkoff from the Cleveland Clinic speaks on the significance of having this new technology available to patients.
Framingham, Reynolds, CRP, calcium..? How best to assess CVD risk in women? Drs Redberg, Hayes, Lloyd-Jones, and Wenger discuss optimal risk stratification, the utility of preclinical screening and the importance of treating traditional risk factors in female patients.
This program will examine the importance of acute and long-term dual antiplatelet therapy to protect ACS patients against thrombotic events. It will also provide information on established treatment guidelines and pivotal evidence-based clinical trial results arising from head-to-head comparisons of antiplatelet treatment options.
What is the prevalence and clinical impact of lead failure on the patient and their QOL? Our panel of experts, Drs Ellenbogen, Epstein, Wilkoff, and Auricchio discuss evidence-based strategies for managing this important issue.
Depression is common in patients with CVD and is associated with poor outcomes. Drs Redberg, Hayes, Vaccarino and Wenger discuss the links between depression and CVD as well as ways to integrate screening and treatment of depression into your practice.
What is the ideal antithrombotic therapy for the management of STEMI patients? Please join Dr Antman and an expert panel as they discuss the latest clinical trial data from the AHA 2006 Scientific Sessions regarding the management of STEMI patients.
